“ Short-Term Treatment With Metformin Improves the Cardiovascular Risk Profile in First-Degree Relatives of Subjects With Type 2 Diabetes Mellitus Who Have a Metabolic Syndrome and Normal Glucose Tolerance Without Changes in C-Reactive Protein or Fibrinogen ”. Clinics 64, no. 5 (May 1, 2009): 415–420. Accessed June 15, 2024. https://www.revistas.usp.br/clinics/article/view/18033.